MSF responds to latest WHO recommendation for a COVID-19 therapeutic baricitinib

14 January 2022

The Janus kinase (JAK) inhibitor baricitinib, marketed by US pharma major Eli Lilly (NYSE: LLY) as Olumiant, is strongly recommended for patients with severe or critical COVID-19 in combination with corticosteroids, an expert group from the World Health Organization has written in the British Medical Journal (BMJ).

The WHO group has also made a conditional recommendation for the use of the monoclonal antibody (MAb) sotrovimab in patients with non-severe COVID-19, but only in those at highest risk of hospital admission, reflecting fewer benefits in those at lower risk.

With the WHO recommending baricitinib for the treatment of people with severe or critical COVID-19, the international medical humanitarian organization Médecins Sans Frontières/Doctors Without Borders (MSF) calls on governments to take immediate steps to ensure that patent monopolies do not stand in the way of access to this treatment.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK